Capitol Hill Briefs
This article was originally published in The Gray Sheet
Executive Summary
Two House bills that seem simple on the surface – one on protecting “good Samaritans” from liability when they use automatic external defibrillators on cardiac arrest victims; one targeting public educational programs for cell-free DNA prenatal screening – sparked debate at a Dec. 9 Energy and Commerce Committee hearing. Also: legislators are attempting to insert device tax repeal provisions into must-pass 2016 agency funding and tax-extender bills.
You may also be interested in...
CMS And FDA Stand Together Behind FDA Oversight Of LDTs At House Hearing
CMS Deputy Administrator for Innovation and Quality Patrick Conway and FDA Device Center Director Jeffrey Shuren told a House subcommittee that legislators’ efforts to replace FDA’s proposed laboratory-developed test framework would lead to duplicative, time-consuming, expensive regulation, and could only result in ineffective and delayed diagnostics that might harm patients.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.